Amid the ongoing public health crisis, Wall Street is eagerly awaiting any piece of good news. Inovio Pharmaceuticals (INO) just came through.On Monday, the vaccine maker, which is up 150% year-to-date, announced that the Investigational New Drug (IND) application for its experimental COVID-19 vaccine, INO-4800, had been accepted by the FDA. Additionally, management revealed that the first patient in the Phase 1 trial had been dosed with the DNA vaccine candidate.Commenting on the development, H.C. Wainwright analyst Raghuram Selvaraju said, “We note that this constitutes a validating milestone for Inovio’s DNA medicine platform—i.e., to rapidly develop and advance a vaccine …read more
Source:: Yahoo Finance
